Caricamento...
What if HIV were unable to develop resistance against a new therapeutic agent?
BACKGROUND: The HIV integrase inhibitor, Dolutegravir (DTG), was recently approved by the Food and Drug Administration in the United States and is the only HIV drug that has not selected for resistance mutations in the clinic when used as part of first-line therapy. This has led to speculation that...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3842747/ https://ncbi.nlm.nih.gov/pubmed/24267867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1741-7015-11-249 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|